REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Inclusion Criteria:

1. High grade serous epithelial ovarian cancer, fallopian tube or primary peritonealcancer

2. Age ≥ 18 years

3. ECOG performance status 0 to 1

4. Positive FOLR1 expression per central laboratory testing

5. Relapsed platinum-resistant epithelial ovarian cancer and received a total of 1 to 3prior regimens

6. Prior bevacizumab treatment is required, if labeled and available as standard ofcare per institutional guidelines, unless subject has documented contraindication

7. At least 1 measurable target lesion per RECIST v1.1

8. Adequate organ function

Exclusion Criteria:

1. Low grade (Grade 1) ovarian carcinoma, clear cell, mucinous, endometrioid,sarcomatous, and mixed histology ovarian carcinomas

2. Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulininhibitor

3. Primary platinum-refractory disease

4. History of severe allergic or anaphylactic reactions to monoclonal antibody therapyor to antibody-related fusion protein treatment

5. Pre-existing clinically significant ocular disorders, severe chronic obstructivepulmonary disease or asthma, clinically significant cardiac or cerebrovasculardisease, or other significant concurrent, uncontrolled medical condition

6. Previous solid organ transplantation

7. History or clinical signs of meningeal or active central nervous system involvement

8. Concurrent participation in another therapeutic treatment trial